Replies to post #4355 on Dendreon Corp fka DNDNQ

[poorgradstudent]

I think you can pretty much narrow your simulation "window" to patients receiving taxotere following progression from 9902B rather than other investigational agents such as the CTLA-4 blockers. Most trials for non-approved drugs will have exclusion criteria relating to prior investigational drug treatment, making Provenge treated patients ineligible.